Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26FCY0D
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,041
Award facts
- Contract value 100% obligated
- $14,040.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $14,040.64 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of January 7, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 31, 2031. This comprehensive IDC serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains.
Repatha (evolocumab) is a PCSK9 inhibitor used for managing high cholesterol in patients at risk for cardiovascular disease, particularly those with familial hypercholesterolemia. The auto-injector formulation supports the Defense Health Agency and military treatment facilities in providing this specialized pharmaceutical therapy to service members and beneficiaries. AmerisourceBergen's demonstrated capability to fulfill federal medical supply requirements through open competition, combined with its established position as a critical vendor in the federal pharmaceutical supply chain, positions the company to efficiently deliver this cardiovascular therapeutic to military healthcare systems.
Quick answers
Who was awarded contract SPE2DR26FCY0D?
SPE2DR26FCY0D was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FCY0D worth?
The government has obligated $14,041 on SPE2DR26FCY0D.
Is contract SPE2DR26FCY0D an order under another contract?
Yes. SPE2DR26FCY0D is a delivery order under SPE2DR25D1100, an indefinite delivery contract.
Was contract SPE2DR26FCY0D competed?
The extent of competition for SPE2DR26FCY0D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award